A production line of Wegovy injection pens at a Novo Nordisk A/S pharmaceutical manufacturing facility. President Donald Trump’s plan to impose a 100% tariff on branded drug imports was greeted with a shrug by many investors, who are betting his exemptions for companies with US manufacturing will soften any blow. While Trump’s move threatens to double the cost of some imported treatments if construction on US manufacturing sites hasn’t begun by Oct. 1, many big drugmakers already have US plants or are bu ...

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Deagreez/iStock via Getty Images Just over 4 months have passed since my last article, "Is Novo Nordisk Immune to President Trump's Drug Price Plans." What was it about? In it, I presented an analysis of the clinical development program for ...

PHILADELPHIA, Sept. 26, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025(the "Class Period"), may, no later than September 30, 2025, seek to be appointed as a lead plain ...

Secretary of Health and Human Services Robert F. Kennedy Jr.The Associated PressTylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.Tylenol may be only the beginning.For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and ...

试验结果概述 - 礼来公司发布头对头试验顶线结果 声称其口服GLP-1药物orforglipron在治疗2型糖尿病方面优于诺和诺德口服版Wegovy [2] - 试验主要终点为降低A1C水平（血糖指标） 礼来36mg剂量组A1C降低2.2% 诺和诺德14mg剂量组降低1.4% [3] - 次要终点体重减轻数据显示 礼来36mg剂量组平均减重9.2% 诺和诺德14mg剂量组减重5.3% [4] 数据背景分析 - 诺和诺德正在试验更高剂量25mg口服司美格鲁肽用于肥胖症治疗 远超礼来试验采用的14mg剂量 [4] - 诺和诺德Oasis 4三期试验显示 25mg剂量口服司美格鲁肽实现平均体重减少16.6% [6] - 礼来试验结果不能证明orforglipron在利润更丰厚的肥胖适应症疗效上优于口服司美格鲁肽 [7] 行业竞争态势 - 两种口服药物均未上市销售 试验结果不代表竞争格局已定 [2] - 头对头试验主要针对2型糖尿病治疗 肥胖症适应症存在不同剂量方案 [3][4][7]

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per share and is deeply undervalued. While they haven't been doing all that well of late, over the long run, they could generate some terrific returns given their low valuations.Here's why you'll want to consi ...

欧洲制药股在早盘交易中下跌，诺和诺德、诺华制药、阿斯利康在德国Tradegate交易平台下跌 1.7%-2%。 （文章来源：第一财经） ...

每经AI快讯，9月26日，诺和诺德在Tradegate交易平台上下跌3%。 ...

一个曾被遗忘近20年的来靶点，正在成为搅动千亿减重市场的新爆点。 9月16日，诺和诺德在欧洲糖尿病研究协会大会（EASD）上公布了Amylin类似物cagrilintide（卡格列 肽）的3期REDEFINE 1研究最新数据。结果显示：治疗68周后，cagrilintide单药治疗实现了11.8%的平 均体重减轻。 更引人瞩目的是，其与司美格鲁肽组成的复方制剂CagriSema，平均减重效果达20.4%，显著优于单药 治疗。与此同时，CagriSema组的胃肠道副作用明显低于司美格鲁肽，做到了控糖与安全性的兼顾。 诺和诺德的布局远不止于此。9月22日，诺和诺德在Clinicaltrials.gov网站上注册了NNC0662-0419用于减 重的2期临床试验，该药物是GLP-1/GIP/Amylin三靶点激动剂（NN9662）。 同日，辉瑞宣布以49亿美元现金以及24亿美元里程碑付款的方式收购Metsera公司，此举动意在强化自 身的减重管线。消息一出，Metsera股价大幅飙升，一度暴涨超63%。 在此之前，罗氏、阿斯利康、礼来、艾伯维等多家国际药企已纷纷通过BD合作或重金收购等方式，加 速押注Amylin。 ...